The EFFect of hIgh-dose ClopIdogrel treatmENT in patients with clopidogrel resistance (The EFFICIENT Trial)

International Journal of Cardiology

Volumn 157, Issue 3, 2012, Pages 374-380

  Ari, Hasan ^a   Ozkan, Hakan ^b   Karacinar, Ali ^a   Ari, Selma ^a   Koca, Vedat ^a   Bozat, Tahsin ^a  

^a Bursa Postgraduate Hospital   (Turkey)

^b MEDICAL PARK HOSPITAL   (Turkey)

Author keywords

Clopidogrel; MACCE; PCI; Resistance

Indexed keywords

CLOPIDOGREL;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84861230787     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.12.083     Document Type: Article

References (42)

1. P. Savi, and J.M. Herbert Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis Semin Thromb Haemost 31 2005 174 183
2. M. Savcic, J. Hauert, F. Bachmann, P.J. Wyld, B. Geudelin, and R. Cariou Clopidogrel loading dose regimens: kinetic, iprofile of pharmacodynamic response in healthy subjects Semin Thromb Hemost 2 1999 15 19
3. J.M. Pereillo, M. Maftouh, and A. Andrieu Structure and stereochemistry of the active metabolite of clopidogrel Drug Metab Dispos 30 2002 1288 1295
4. The CAPRIE Steering Committee A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet 348 1996 1329 1339
5. B.S. Lewis, S.R. Mehta, and K.A. Fox CURE trial investigators. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study Am Heart J 150 6 2005 Dec 1177 1184
6. N. Von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schömig, A. Kastrati, and A. Schömig Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900 mg loading doses of clopidogrel. Results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3 high oral doses for immediate clopidogrel effect) trial Circulation 112 2005 2946 2950
7. N. von Beckerath, A. Kastrati, and A. Wieczorek A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 2007 1814 1819
8. D.J. Angiolillo, S.B. Shoemaker, and B. Desai Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716
9. P. Fontana, D. Senouf, and F. Mach Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness Thromb Res 121 2008 463 468
10. D.J. Angiolillo, M.A. Costa, and S.B. Shoemaker Functional effect of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment Am J Cardiol 101 2008 440 445
11. B. Aleil, L. Jacquemin, and F. De Poli Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study J Am Coll Cardiol Intv 1 2008 631 638
12. S.C. Smith Jr., T.E. Feldman, and J.W. Hirshfeld Jr. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001) Circulation 113 2006 166 286
13. A.K. Rao, C. Pratt, and A. Jaffe Thrombolysis In Myocardial Infarction (TIMI) trial - phase 1: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase J Am Coll Cardiol 11 1988 1 11
14. Shao Chow, and Wang Sample size calculations In clinical research 2003 Taylor & Francis NY 88
15. R.G. Newcombe, and D.G. Altman Proportions and their differences D.G. Altman, Statistics with confidence - confidence intervals and statistical guidelines 2nd ed London: British Medical Journal 4 2000 45 56
16. D.J. Angiolillo, M.A. Costa, and S.B. Shoemaker Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment Am J Cardiol 101 2008 440 445
17. W.C. Lau, P.A. Gurbel, and P.B. Watkins Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance Circulation 109 2004 166 171
18. P.A. Gurbel, K.P. Bliden, and W. Samara Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study J Am Coll Cardiol 46 2005 1827 1832
19. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
20. C. Patrono, B. Coller, G.A. FitzGerald, J. Hirsh, and G. Roth Platelet active drugs: the relationships among dose, effectiveness, and side effects. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 234 264
21. T. Cuisset, C. Frere, and J. Quilici Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting J Am Coll Cardiol 48 2006 1339 1345
22. L. Bonello, L. Camoin-Jau, and S. Arques Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study J Am Coll Cardiol 51 14 2008 1404 1411
23. D.P. Chew, D.L. Bhatt, and M.A. Robbins Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein Am J Cardiol 88 2001 672 674
24. T. Heitzer, V. Rudolph, and E. Schwedhelm Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects Arterioscler Thromb Vasc Biol 26 2006 1648 1652
25. T. Göncü, O. Tiryakioǧlu, and A. Ozcan Inhibitory effects of ticlopidine and clopidogrel on the intimal hyperplastic response after arterial injury Anatolian J Cardiology 10 1 2010 11 16
26. A. Warnholtz, M.A. Ostad, and N. Velich A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study Atherosclerosis 196 2008 689 695
27. L.H. Yang, and J. Fareed Vasomodulatory action of clopidogrel and ticlopidine Thromb Res 86 1997 479 491
28. P.M. Ho, E.D. Peterson, and L. Wang Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome JAMA 299 2008 532 539
29. S.R. Mehta, and F. Van de Werf CURRENT OASIS 7 trial results: a randomized comparison of a clopidogrel high loading and maintenance dose regimen versus standard dose and high versus low dose aspirin in 25,000 patients with acute coronary syndromes ESC Congr Aug. 29-Sep. 02 2009
30. M.J. Price GRAVITAS investigators. Primary results of the gauging responsiveness with AVerifyNow assay - impact on thrombosis and safety AHA Sci Sess November 14 - 17 2010
31. S.C. Smith Jr., T.E. Feldman, and J.W. Hirshfeld Jr. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association task force on practice guidelines Circulation 113 2006 166 286
32. Y.H. Jeong, S.W. Lee, and B.R. Choi Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol 53 13 2009 1101 1109
33. N. Tavassoli, S. Voisin, and D. Carrie High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients Am J Cardiovasc Drugs 10 1 2010 29 35
34. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management and future perspectives J Am Coll Cardiol 49 2007 1505 1516
35. D.J. Angiolillo ADP receptor antagonism: what's in the pipeline? Am J Cardiovasc Drugs 7 2007 423 432
36. W.H. Chen, P.Y. Lee, W. Ng, H.F. Tse, and C.P. Lau Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment J Am Coll Cardiol 43 2004 1122 1126
37. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, and E.J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961 965
38. J.W. Eikelboom, J. Hirsh, J.I. Weitz, M. Johnston, Q. Yi, and S. Yusuf Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 105 2002 1650 1655
39. A. Malinin, A. Pokov, and M. Spergling Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study Thromb Res 119 3 2007 277 284
40. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251
41. N.J. Breet, J.W. van Werkum, and H.J. Bouman Do platelet function assays predict clinical outcomes in clopidogrel pretreated patients undergoing elective PCI (POPULAR) AHA Sci Sess November 14-18 2009
42. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2